共 81 条
- [1] Sivaprasad S(2012)Ethnic variations in the prevalence of diabetic retinopathy in people with diabetes attending screening in the United Kingdom (DRIVE UK) PLoS One 7 e32182-2405
- [2] Gupta B(2010)Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study) Diabetes Care 33 2399-2151
- [3] Gulliford MC(2010)Two-year outcomes of the ranibizumab for edema of the macula in Diabetes (READ—2) Study Ophthalmology 117 2146-801
- [4] Dodhia H(2012)Ranibizumab for diabetic macular edema. Results from 2 Phase III Randomized trials: RISE and RIDE Ophthalmology 119 789-2022
- [5] Mann S(2013)Long-term outcomes of ranibizumab therapy for diabetic macular edema: The 36-month results from two phase III Trials. RISE and RIDE Ophthalmology 120 2013-1203
- [6] Nagi D(2015)Diabetic Retinopathy Clinical Research Network. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema N Engl J Med 372 1193-370
- [7] Massin P(2012)Prevalence of diabetic retinopathy in various ethnic groups: A world-wide perspective Surv Ophthalmol 57 347-269
- [8] Bandello F(2009)The effect of ethnicity on the prevalence of diabetes and associated chronic kidney disease QJM 102 261-e14
- [9] Garweg JG(2011)Rationale for the diabetic retinopathy clinical research network treatment protocol for centre-involving diabetic macular edema Ophthalmology 118 e5-625
- [10] Hansen L(2011)The RESTORE Study. Ranibizumamb monotherapy or combined with laser versus laser monotherapy for diabetic macular edema Ophthalmology 118 615-2318